Fanconi anemia (FA) is a rare genetic disorder associated with a high frequency of hematological abnormalities and congenital anomalies. Based on multilateral efforts from basic scientists and clinicians, significant advances in our knowledge of FA have been made in recent years. Here we review the clinical features, the diagnostic criteria, and the current and future therapies of FA and describe the current understanding of the molecular basis of the disease.

**Diagnosis of FA**

Fanconi anemia (FA) is a genetic disorder characterized by multiple congenital anomalies and hematological abnormalities and predisposition to a variety of cancers (Figure 1). The classic diagnostic test for FA is the assessment of cellular hypersensitivity to DNA interstrand crosslinking agents (ICLs), such as diepoxybutane (DEB) and mitomycin C (MMC) (1, 2). Exposure of FA cells to these agents results in high levels of chromosomal aberrations, particularly chromosomal breaks and radial formations. The DEB-induced chromosome breakage assay (DEB test) has been widely used for the primary diagnosis of FA. Due to possible somatic mosaicism (i.e., the presence of two or more cell populations with different genotypes), measuring the percentage of cells with aberrations is more informative than measuring the number of aberrations per cell. The chromosome breakage test yields occasional false positives, as other genetic disorders, such as Nijmegen breakage syndrome and Roberts syndrome, also display aberrant chromosomes upon exposure to these DNA ICLs (3).

Examining the cell cycle profile of peripheral blood lymphocytes is also useful in diagnosing FA. FA cells display a marked increase of cells in G2/M phase (4N DNA content), either before or after treatment with DNA ICLs. However, the definitive diagnostic test is the complementation test, also known as FA subtyping. In this test, patient-derived FA cells are transduced with retroviruses that carry cDNAs complementing the different FA subtypes. Transduction with the appropriate FA complementation group (FANC) cDNA will correct the cellular FA phenotypes, such as the chromosomal aberrations and hypersensitivity to DNA ICLs. In addition, clinical manifestations such as short stature, skeletal deformities, and café-au-lait spots on skin can aid diagnosis (4). An early diagnosis of FA is important for clinical management, particularly because FA patients are predisposed to multiple malignancies (see below).

**Pathophysiology of FA**

Individuals with FA display several congenital defects, but approximately 25%–40% of FA patients are physically normal (1). Approximately half of children with FA have congenital skeletal anomalies, frequently of the thumb and forearm. The thumbs are usually smaller (hypoplastic), duplicated, or absent. The radius of the forearm may also be smaller or absent (5). Many FA individuals display endocrine abnormalities. Approximately half of FA individuals have short stature, correlating with insufficient growth hormone production and hyperthyroidism. Some FA individuals have normal stature and do not have an obvious deficiency in growth hormone production. Additionally, abnormal glucose or insulin metabolism is associated with FA. As opposed to reduced insulin in diabetes, FA individuals usually have a higher level of serum insulin. Approximately 8% of individuals with FA are reported to be diabetic, while up to 72% showed elevated insulin (6, 7). In addition, osteoporosis is associated with FA (6–9).

Hematologic abnormalities represent the most prevalent pathologic manifestation of FA. Approximately 75%–90% of FA patients develop bone marrow failure, ranging from mild to severe, during the first decade of life (10, 11). In addition, most FA individuals develop varying degrees of blood disease, including aplastic anemia, myelodysplastic syndrome (MDS), or acute myeloid leukemia (AML). The risk of AML occurrence is approximately 800-fold higher than that of the general population, with a median age of onset of 14 years. Recent reports revealed a common pattern of specific chromosomal abnormalities in FA patients with MDS or AML (e.g., gain of 1q23-32, 3q26), which suggests that these abnormalities can be useful predictive markers (4, 12–14). The exact cause of these hematopoietic defects is unclear, although increasing evidence suggests an underlying intolerance of FA hematopoietic cells to oxidative stress (15).

Although FA is mainly a pediatric disease, adult FA patients (>18 years of age) now represent an increasing proportion of the FA patient population due to improved management of young FA patients and more rigorous diagnostic testing in adults. A major health threat faced by adult FA patients is the risk of cancer (16). In addition to hematologic cancers, solid tumors, particularly squamous cell cancers (SCCs) of the head and neck and cervical/gynecological cancers, occur at markedly higher rates in FA patients (17). Approximately one-third of FA patients will develop a solid tumor by the fourth decade of life (18). The relative contribution of human papillomavirus (HPV) infection to SCC in FA patients is unknown, and published studies have yielded conflicting results (19–21).

Conflict of Interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2012;122(11):3799–3806. doi:10.1172/JCI58321.
In addition to the hematological abnormalities and increased cancer susceptibility, FA individuals exhibit other clinical problems, such as hearing loss and ear anomalies as well as reduced fertility (5). Reduced sperm count is associated with male FA patients, and premature menopause is associated with female patients (22). The rate of successful pregnancy is approximately 15% among nontransplanted FA patients (22), although patients (22). The rate of successful pregnancy is approximately 15% among nontransplanted FA patients (22), although improved fertility and pregnancy after HSC transplantation (HCT) has been reported (23). Consistent with the reduced fertility in FA patients, some studies on knockout mouse models of Fanca, Fancc, and Fancd2 showed pronounced hypogonadism and impaired fertility, with females more severely affected than males (24, 25).

**Biology of FA**

**FANCs.** To date, 15 FANCs have been identified (FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCJ, FANCL, FANCM, FANCN, FANCO, and FANCP; Table 1). The majority of FA genes are located on autosomes, with the exception of FANCA, which is on the X chromosome. FA patients with mutations in any of these FA genes share a characteristic clinical and cellular phenotype, and these 15 gene products appear to function in a common cellular pathway, termed the *Fanconi anemia pathway* (26). Indeed, mutations in eight FA subtypes (FANCA, FANCB, FANCC, FANCD, FANCE, FANCF, FANCG, FANCL, and FANCM) result in loss of FANCD2 and FANCI monoubiquitination, the central regulatory event in the FA pathway. Mutations in these eight upstream genes account for approximately 90% of patients (Table 1). Identification of the breast cancer susceptibility gene *BRCA2* as an FA gene (*FANCD1*; ref. 27) reaffirm the close cooperative relationship between the FA pathway and the breast and ovarian tumor-suppressive BRCA proteins BRCA1 (28) and BRCA2 in DNA repair mechanisms. Subsequent identification of FANCN (also known as partner and localizer of BRCA2 [PALB2]; refs. 29, 30), FANCJ (also known as BRCA1-interacting helicase1 [BRIP1]; refs. 31, 32), and, more recently, FANCO (RAD51C; a previously known homologous repair factor; refs. 33, 34) further solidify the close association of breast and ovarian susceptibility genes with FA.

**Table 1**

15 FA subtypes

<table>
<thead>
<tr>
<th>Gene (alias)</th>
<th>Locus</th>
<th>Mutation frequency</th>
<th>Amino acids</th>
<th>Protein MW (kDa)</th>
<th>Notable protein function</th>
</tr>
</thead>
<tbody>
<tr>
<td>FANCA</td>
<td>16q24.3</td>
<td>–66%</td>
<td>1,455</td>
<td>163</td>
<td>Scaffold for FA core complex</td>
</tr>
<tr>
<td>FANCB</td>
<td>Xp22.31</td>
<td>–2%</td>
<td>859</td>
<td>95</td>
<td>Scaffold for FA core complex</td>
</tr>
<tr>
<td>FANCC</td>
<td>9q22.3</td>
<td>–10%</td>
<td>558</td>
<td>63</td>
<td>Scaffold for FA core complex</td>
</tr>
<tr>
<td>FANCD1 (BRCA2)*</td>
<td>13q12.3</td>
<td>–2%</td>
<td>3,418</td>
<td>380</td>
<td>Recruits RAD51 and promotes HR repair</td>
</tr>
<tr>
<td>FANCD2</td>
<td>3p25.3</td>
<td>–3%</td>
<td>1,451</td>
<td>162</td>
<td>Monoubiquitinated. Recruits FAN1, FANCP to chromatin</td>
</tr>
<tr>
<td>FANCE</td>
<td>6p21.3</td>
<td>–2%</td>
<td>536</td>
<td>60</td>
<td>Scaffold for FA core complex. Probable adaptor for FANCD2</td>
</tr>
<tr>
<td>FANCF</td>
<td>11p15</td>
<td>–2%</td>
<td>374</td>
<td>42</td>
<td>Scaffold for FA core complex</td>
</tr>
<tr>
<td>FANCG (XRCC9)</td>
<td>9p13</td>
<td>–10%</td>
<td>622</td>
<td>70</td>
<td>Monoubiquitinated. Forms heterodimer with FANCD2</td>
</tr>
<tr>
<td>FANCI</td>
<td>15q25-26</td>
<td>&lt;2%</td>
<td>1,328</td>
<td>150</td>
<td>Interacts with BRCA1. DNA helicase, ATPase</td>
</tr>
<tr>
<td>FANCI (BACH1, BRIP1)*</td>
<td>17q22.3</td>
<td>&lt;2%</td>
<td>1,249</td>
<td>150</td>
<td>Recruits UBE2T via PHD E3 domain. Monoubiquitinates FANCD2 and FANC1</td>
</tr>
<tr>
<td>FANCL (PHF9)</td>
<td>2p16.1</td>
<td>Rare</td>
<td>375</td>
<td>43</td>
<td>Scaffold for FA core complex. Branch migration/ATPase activity. Interacts with BLM</td>
</tr>
<tr>
<td>FANCM</td>
<td>14q21.3</td>
<td>Rare</td>
<td>2,014</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>FANCN (PALB2)*</td>
<td>16p12.1</td>
<td>Rare</td>
<td>1,186</td>
<td>130</td>
<td>Mediates interaction between BRCA1 and BRCA2 during HR</td>
</tr>
<tr>
<td>FANC0 (RAD51C)*</td>
<td>17q22</td>
<td>Rare</td>
<td>376</td>
<td>43</td>
<td>Promotes HR. Interacts with RAD51 and RAD51 homologs</td>
</tr>
<tr>
<td>FANCP (SLX4)*</td>
<td>16p13.3</td>
<td>Rare</td>
<td>1,834</td>
<td>200</td>
<td>Functions as holiday junction resolvase with SLX1. Interacts with XPF-ERCC1 and EME1-MUS81 nuclease</td>
</tr>
</tbody>
</table>

*Familial susceptibility to breast cancer. **Familial breast cancer susceptibility unclear (minor, if any).
intervention, such as unrelated donor bone marrow transplantation. Patients with FANC1D have earlier onset and increased incidence of leukemia and solid tumors (35). In general, early diagnosis and identification of FANC mutations is critical for the informed genetic counseling of parents of FA patients with regard to future pregnancies.

**Role of the FA pathway in DNA repair during S phase.** DNA ICLs are highly toxic lesions that block essential DNA metabolism, such as DNA replication and transcription. Hypersensitivity to ICL in FA is associated with the accumulation of G2/M-arrested cells. The cell cycle arrest at G2/M is due to increased activity of checkpoint kinase CHK1, and depleting CHK1 suppresses the G2/M arrest (36). These observations suggest that FA cells are inherently defective in repairing DNA damage. Indeed, increasing evidence affirms that the FA proteins are directly involved in repairing damaged DNA (26).

Among the 15 FA gene products identified so far, the eight upstream FA proteins (FANCA, FANCB, FANCC, FANCE, FANCF, FANCN, FANCL, and FANCM) form a nuclear complex, termed the **FA core complex**, which possesses intrinsic E3 ubiquitin ligase activity (Figure 2). Most FA proteins in the FA core complex do not contain any recognizable enzymatic domain, which suggests that their primary function is a scaffold (Table 1). The key domain in the complex is the PHD-type RING finger domain at the C terminus of FANCL. The PHD domain interacts with an E2 ubiquitin–conjugating enzyme, UBE2T, depletion of which in cultured cells leads to a characteristic FA phenotype (37). The primary function of the FA core complex is to monoubiquitinate two FA proteins, FANCD2 and FANCI, which are expressed as a constitutive heterodimer (38, 39). A crystal structure of the FANCD2/FANCI heterodimer (also referred to as the ID complex) suggests that this complex can recognize various DNA structures that may arise from stalled replication forks (40); however, how monoubiquitylation affects the activity or conformation of this heterodimer is unknown. Monoubiquitylated FANCD2 serves as a signal for recruiting downstream effectors that have affinity for the ubiquitin. Fanconi-associated nuclease 1 (FAN1) is recruited to the monoubiquitylated form of FANCD2 via its ubiquitin-binding UBZ domains (41–44) and is thought to participate in ICL repair through its nucleolytic activity.

The major DNA repair pathway regulated by the FA proteins is homologous recombination (HR), a process that repairs DNA double strand breaks (DSBs). DSBs are intermediate lesions during ICL repair, and HR is critical to their repair. Cells lacking FA proteins are deficient in promoting HR activities. Although the mechanism remains unclear, monoubiquitylated FANCD2/FANCI is thought to functionally associate with the downstream FA proteins critical for HR, including FANC1D (i.e., BRCA2; 45, 46), FANCN (PALB2; ref. 47), and possibly FANCJ (BACH1; ref. 32). FANCD2 also colocalizes with key HR factors, such as BRCA1 and RAD51 (48). Although the upstream FA proteins are required for HR activity, the degree of the HR defect is milder compared with defects resulting from loss of the downstream FA proteins. FANCD2/FANCI proteins do not appear to directly regulate chromatin loading of the key HR enzyme RAD51 (49). However, RAD51 activity is directly regulated by FANCD1, FANCN, and FANCO, possibly accounting for the phenotypic differences. These downstream FA proteins are also potentially involved in a wider range of repair mechanisms and not limited to ICL repair.

FA proteins may promote HR activity by different mechanisms. Recent reports suggest that FA proteins actively suppress nonhomologous end-joining (NHEJ), an error-prone DSBR repair mechanism that functions during the G1 phase of the cell cycle (50, 51). Improper activation of NHEJ factors was observed in FA pathway-deficient cells, resulting in chromosomal rearrangements and aberrations during S phase. Several mechanisms are possible: (a) FA proteins may restrict the access of NHEJ factors, such as the Ku70-80 heterodimer, to the DSBR ends during the ICL repair process; or (b) cryptic nucleolytic activity of FANCD2 may generate DNA structures at DSBR ends recognized by HR factors (1, 27, 51).

In addition to HR, FA proteins coordinate both nucleolytic incision and DNA translesion synthesis (TLS) during ICL repair. The current model suggests that replication fork stalling by ICL requires subsequent incision of the ICL flanking lesion and unhinging of the ICL by endonuclease activities (26, 52). Recruitment of endonucleases MUS81-EME1 or XPF-ERCC1 is likely involved in this step, although genetic studies indicate that XPF-ERCC1 may be the more relevant enzyme in the FA pathway (53, 54). In addition, Fan1 or SLX4-SLX1 nucleases may also be involved in this step. Incision of ICL is followed by TLS, a damage tolerance mechanism in which specialized low-fidelity polymerases bypass bulky damaged lesions. Cells with disrupted TLS polymerase (e.g., REV3) display FA-like phenotypes, such as hypersensitivity to DNA ICLs (55, 56). A biochemical study using the *Xenopus* replication system demonstrated that the monoubiquitylated FANCD2/FANCI complex is required for both nucleolytic incision and TLS steps during ICL repair (57). Although the incision step is not required for monoubiquitylation of FANCD2, it may be required for the chromatin recruitment of FANCD2 (58). Interest-
ingly, SLX4, a scaffold protein that binds to MUS81-EME1, XPF-ERCC1, and SLX1 endonucleases, was recently identified as a the fifteenth FA subtype, FANCP (59–61). FANCP is not required for FANCD2 monoubiquitylation, but contains two U2B domains that are required for recruitment to monoubiquitylated FANCD2 (62). Several additional FA-associated proteins are integral to the pathway. These include FA-associated protein 24 kDa (FAA2P; ref. 63), FAA1P100 (64), FANCM-associated histone fold protein 1 (MHF1), and MHF2 (26, 65), all of which are part of the FA core complex. The recently identified FAA2P20 is also an integral part of the FA core complex (66–68). Cells rendered deficient in these FA-associated proteins display the classical FA phenotypes, including sensitivity to DNA ICLs and G2/M cell cycle arrest. However, FA patients with these genetic mutations have not been found, so these genes do not have FANC assignments.

In addition to these FA or FA-associated proteins, the FA pathway network broadly includes other regulatory proteins. Ubiquitin-specific peptidease 1 (USP1) and the USP1-associated protein (UAAP1) regulate deubiquitination of FANCD2/FANCI and are required for completion of the FA pathway (69, 70). The ATR/ATRIP heterodimer is required for sensing single-strand DNA generated during S phase and for the induction of FANCD2/FANCI monoubiquitylation in response to DNA damage (71). Proteins involved in ATR signaling, such as RPA (single-strand DNA binding protein), RAD17, RAD9 (9-1-1 checkpoint complex), CHK1, and HCL2, are required for the efficient induction of FANCD2/ FANCI monoubiquitylation (36, 72). FA proteins also crossstalk with MSH2/MSH3 mismatch proteins (73) and BLM helicase (74, 75) during ICL repair. Thus, defective DNA repair mechanisms during S phase may render FA cells vulnerable to endogenous damage or oxidative stress.

Role of the FA pathway in cytokinesis. The primary DNA repair function of the FA pathway is exerted during S phase. However, the role of FA proteins may extend to M phase, especially in cytokinesis. FA cells exhibit instability at chromosomal fragile sites, the regions in the mitotic chromosomes that serve as a marker for unrepaired DNA (76, 77). A series of recent studies suggested that the FA proteins provide a surveillance mechanism for monitoring unrepaired DNA during cytokinesis (78–80). Fragile sites were stained with FANCD2 and FANCI, and the absence of these FA proteins in these sites was associated with increased chromosome instability and binucleated cells (cells containing two nucleuses). These binucleated cells underwent apoptosis and are a potential cause of bone marrow failure in FA. The fragile sites are connected with mitotic DNA structures called ultrafine DNA bridges (UFBs). Replication errors during S phase may increase UFB structures during M phase, possibly more so in FA cells, which may cause failure in cytokinesis and generation of binucleated cells. The normal function of the FA proteins at the fragile sites and UFB remains uncertain. Several other DNA repair proteins that are linked to the FA pathway, such as ATR, BRC1,1, and RAD51, also regulate the stability of fragile sites, suggestive of a broader role of the FA-BRCA network during cytokinesis.

Management of FA patients

Treatment of bone marrow failure. Bone marrow failure in FA patients typically develops during the first decade of life (81). Androgen therapy is effective for treating bone marrow failure in some FA patients. Synthetic androgens, such as oxymetholone and danazol, have been effective in treating hematopoietic defects in FA patients (82, 83), although long-term androgen use has side effects that include hirsutism and increased liver tumor incidence. Although androgens increase red blood cell counts and platelet counts (84), the exact mechanism of androgens in the hematopoietic system is unclear. Hematopoietic growth factors (e.g., G-CSF and GM-CSF) have been helpful in improving the neutrophil counts in FA (82).

HCT remains the primary treatment of choice for bone marrow failure in FA. Because of the underlying DNA repair defect in FA, extensive chemoradiaation used in the transplantation procedure can be highly toxic. Histocompatible (matched) sibling donor transplant remains the best treatment for FA and gives the best outcome, if performed early (i.e., prior to the development of MDS or leukemia; refs. 81, 85). Still, transplant survivors experience multiple complications, including physical injury from chemoradiaation (including pulmonary and renal toxicity and veno-occlusive disease), graft-versus-host disease (GVHD), immune injury, sterilility, and endocrinopathies. Optimization of the HCT conditioning regimen, such as use of lower-dose cyclophosphamide (alkylating agent), a fludarabine-based reduced-intensity regimen (immuno-suppressive), or nonirradiation, continue to limit these complications while maintaining sufficient engraftment rates (85–89). As most FA patients do not have a histocompatible sibling, some families have turned to preimplantation genetic diagnosis (PGD) for generation of a suitable donor (90). HCT from alternate (unrelated or HLA mismatched) donors is associated with a higher risk of complications and a lower survival rate. However, the survival rate of alternate-donor HCT has improved steadily since Gluckman and colleagues initially reported the outcome of alternate-donor HCT for FA patients in 1995 (91). More recently, reduction of the irradiation in the conditioning regimen has limited the toxic effects and improved the survival rates of alternate-donor HCT (89). While HCT is highly successful in extending the life expectancy of FA patients, managing the long-term complications of HCT now has greater importance. Additionally, HCT does not treat nonhematopoietic complications of FA, such as increased cancer susceptibility.

Gene therapy. There has been a resurgence of interest in gene therapy for FA. In many ways, FA is an ideal candidate disease for gene therapy. Subtyping FA patients is relatively straightforward, allowing identification of the mutant FA gene and generation of retroviral or lentiviral vectors carrying the wild-type cDNA to complement cells. Transduced and cDNA-complemented cells should have a clear selective advantage in vivo over endogenous marrow cells. Furthermore, gene therapy provides a method for generation of autologous donor cells. However, successful gene therapy for FA has been delayed by several technical obstacles. First, FA patients lack sufficient HSCs for ex vivo transduction. Accordingly, marrow should be collected and stored early in the life of the FA patient. New methods are needed to expand FA bone marrow cells ex vivo, which could potentially be developed with the use of HOXB4 and DELTA-1 (92). Second, improvements in the efficiency of viral transduction are required. The benefit of reducing oxidative stress, combined with shorter ex vivo transduction periods, has been shown for improving gene transduction efficiency in FA HSCs and may hold promise for enhancing FA gene therapy (93). Finally, gene therapy continues to pose a risk of leukemia, driven by the integration of the therapeutic vector near a proto-oncogene, followed by the expansion of a malignant clone. Improvements in conditioning regimens and in the generation of self-inactivating retroviral vectors and lentiviral vectors may further improve the efficiency and safety of gene therapy for FA.
Table 2
Potential future therapies for FA

<table>
<thead>
<tr>
<th>Therapeutic approach</th>
<th>Rationale</th>
<th>Potential limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improved gene therapy</td>
<td>Improving sufficient isolation of FA HSCs through genetic manipulations. Difficulty in finding matched sibling donors for HCT, and the effects observed in somatic mosaic patients, wherein a small number of revertant cells are able to reconstitute hematopoietic counts</td>
<td>Potential insertional mutagenesis and malignant outgrowth of mutant clones. Questionable long-term ability of graft cells to maintain hematopoiesis</td>
</tr>
<tr>
<td>Antioxidative compounds</td>
<td>ROS is a significant source of endogenous DNA damage, particularly for FA. Reducing ROS rescues FA phenotypes in mouse models and human cell cultures</td>
<td>Excessive usage of antioxidants may cause DNA damage–induced apoptosis</td>
</tr>
<tr>
<td>Small molecule inhibitors (e.g., inhibitors of CHK1, DNA-PK, p38 MAP kinase)</td>
<td>Suppressing CHK1 confers clinical improvements in some FA patients. Inhibiting NHEJ pathway suppresses FA phenotypes in vitro cell cultures and C. elegans model. Inhibiting MAP kinase suppress TNF-α sensitivity of FA cells in vitro</td>
<td>Long-term use of the inhibitors may enhance tumorigenesis or immune suppression</td>
</tr>
<tr>
<td>Ex vivo graft of revertant HSCs</td>
<td>Spontaneous (natural) correction of mutant FA genes is associated with improved clinical modifications. The small number of revertant HSCs can potentially be isolated and expanded in vitro, which will circumvent ectopic gene correction</td>
<td>Long-term ability of the graft cells for hematopoietic functionality questionable</td>
</tr>
<tr>
<td>IPS</td>
<td>Difficulty of finding matched sibling donors of HCT and difficulty of isolating sufficient amount of HSCs for ex vivo genetic manipulation can be overcome by IPS technology</td>
<td>Oncogenic potential of virus-mediated gene insertion can be problematic. Reprogramming efficiency must be improved for clinical applications</td>
</tr>
</tbody>
</table>

Treatment for endocrine dysfunction. Hypothyroidism is observed for many FA patients. One study found that thyroid treatment in FA children with short stature for 7 months led to significant growth improvement, suggesting that FA children with short stature may benefit from thyroid treatment (94). Approximately 50%–70% of FA children have growth hormone deficiency, and extra growth hormone is usually given for these individuals (94, 95). Whether there is an increased risk of AML or other cancers in response to long-term growth hormone treatment remains controversial.

Management of cancers. FA patients have a high frequency of AML and SCCs of the head and neck and gynecologic system (16, 96). With the prolonged survival after successful transplantation, treating and managing FA-related cancers remains an important challenge. Due to the cytotoxicity of chemo- and radiotherapeutic regimens for FA patients, the treatment of FA-related cancers must differ from the treatment strategy for non-FA individuals. Prevention and close surveillance of cancer occurrence are critical elements of FA patient clinical management. FA patients must have annual bone marrow aspirates to rule out premalignant clonal expansion and frequent dental evaluations to rule out early oral cavity SCCs. Women with FA require frequent gynecologic exams to identify early SCCs, and any FA patients should receive HPV vaccinations. Some FA subtype–specific patterns of cancer exist. For instance, patients with subtype D1 have earlier onset and increased incidence of leukemia and solid tumors. FANCD1 mutations are associated with a variety of tumors, including Wilms tumor, neuroblastoma, and brain tumors such as medulloblastoma (35, 97, 98). Moreover, heterozygote carriers from FA subtype D1, J, N, and O families may be predisposed to breast, ovarian, and pancreatic cancers.

Future of FA therapy
Despite a greater understanding of the biology of FA, the mechanisms underlying the hematopoietic defects, developmental defects, and bone marrow failure of FA remain elusive. The defective DNA repair capacity of FA stem cells may underlie their hypersensitivity to endogenous DNA damage, such as damage from ROS (15, 99) or from serum formaldehyde (100, 101). Such hypersensitivity may lead to decreased hematopoietic cellularity (stem cell loss in early development), similar to phenotypes observed in ATM-deficient or ligase IV–deficient (LIG4-deficient) mice (102, 103). Therefore, limiting the potential sources of endogenous DNA-damaging agents may protect HSCs in FA. A recent study showed that resveratrol, an activator of SIRT1 with antioxidant effect, partially rescues the hematopoietic defects of Fancd2–/– mice (104), which suggests that increased sensitivity to ROS is a contributing factor in FA. Antioxidants may also delay tumor onset in FA; the antioxidizing small molecule Tempol was shown to delay tumor formation in a Fancd2−/−Trp53−/− mouse model (105). Screening of small molecules or natural compounds that rescue the hematopoietic defects in FA, particularly those that reduce oxidative DNA damage, may hold promise for future FA therapies.

Several reports provide evidence of somatic reversion in FA, leading to mosaicism. Mosaicism results from spontaneous reverse mutations that restore functional FA alleles (106–109). Reverse mosaicism in FA can provide a selective advantage, and the corrected HSCs can improve clinical outcome. Reverse mosaicism, often referred to as natural gene therapy, suggests that replenishing even a limited fraction of corrected HSCs can significantly improve the hematopoietic defects in FA. The revertant FA stem cells could, in principle, be isolated, expanded in vitro, and grafted back to the patient as an autologous transplant (Table 2). Successful attempts have been made to transplant revertant keratinocytes as a treatment for skin disorders (110, 111). However, questions remain about the ability of corrected cells to sustain the hematopoietic functionality in the long term. Furthermore, the nonrevertant FA cells are still prone to the development of a malignant clonal abnormality (112). Spontaneous mutations in non-FA genes might confer a selective growth advantage to the corrected clones in FA. Individuals with FA were identified by acquired clonal selection of
cells with downregulated ATR-CHK1 proteins and abrogated G2/M checkpoint (113). These individuals had mild bone marrow abnormalities and lived to adulthood, which suggests that G2/M checkpoint abrogation has clinical benefits for FA cells. Long-term effectiveness is questionable, however, as some of these patients eventually develop leukemia or myelodysplasia.

The bone marrow failure in FA individuals may result from hyperactive checkpoint responses in hematopoietic stem and progenitor cells (HSPCs). Primary bone marrow cells from FA patients have elevated levels of p53 and of its downstream effector protein, p21 (A.D. D’Andrea, unpublished observations). Elevated p53 and p21 appear to account, at least in part, for the enhanced cell cycle arrest and apoptosis of HSPCs in the bone marrow of FA patients. A similar mechanism of p53-mediated bone marrow apoptosis has been observed in another inherited bone marrow failure syndrome, Diamond-Blackfan anemia (114). Small molecule inhibitors of p53 may, in principle, rescue this HSPC apoptosis and improve hematopoiesis in FA patients, but at the risk of increasing leukemia incidence.

Finally, induced pluripotent stem cell (iPS) technology holds promise for FA therapy (Table 2). Direct reprogramming of FA promise somatic cells into pluripotent stem cells, which retain the patient’s unique genetic background, may provide a new source of autologous cells for transplant (115). The limitations of traditional gene therapy (e.g., difficulty in isolating sufficient HSCs) and the complications associated with bone marrow transplantation may be avoided by transplanting DNA-corrected iPS cells to FA patients (115, 116). Several issues must be resolved before successful application to the clinic. As for all iPS approaches, use of proto-oncogenes and viral-mediated gene insertion increases the risk of oncogenesis. A safer and more sequence-specific method of gene introduction will be required. Also, the reprogramming efficiency of FA cells must be improved. Knockdown of the FA pathway leads to loss of self-renewal potency, which suggests that a functional FA pathway is required for induction and maintenance of pluripotency (115). However, a recent study demonstrated that functional complementation of the FA pathway restores the reprogramming efficiency of FA patient cells, providing a strategy in FA-specific iPS generation (117). Finally, successful induction of blood progenitors from iPS cells, capable of long-term hematopoietic reconstitution, at a scale compatible for transplantation in FA patients remains a challenge (116, 118). Despite these challenges, iPS technology offers the promise of generating tissue-compatible transplants for all FA patients.

Acknowledgments

We apologize for those whose work is not cited due to space limitations. We thank Alexandra Feinstein for critical reading of the manuscript. This work was supported by NIH grants R01DK43889, R37HL52725, and 2P01HL048546 to A.D. D’Andrea and by departmental startup funds to Y. Kee.

Address correspondence to: Younghoon Kee, University of South Florida, Department of Cell Biology, Microbiology, and Molecular Biology, 216 Bio-Science Facility Building, Tampa, Florida 33620, USA. Phone: 813.974.5352; Fax: 813.974.1614; E-mail: ykee@usf.edu. Or to: Alan D. D’Andrea, Dana Farber Cancer Institute, Radiation Oncology, Mayer Bldg., Rm. 640, 450 Brookline Ave., Boston, Massachusetts 02215, USA. Phone: 617.632.2112; Fax: 617.632.5757; E-mail: alan_dandrea@dci.harvard.edu.


